Which means if adequate solid evidence comes in with the treatment method, the FDA will rapidly-keep track of its review approach. The FDA has given exactly the same designation to MAPS for its work on MDMA-assisted psychotherapy for PTSD. As the largest-to-date clinical trial of psilocybin is about to https://fridav469zef5.wikistatement.com/user